Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Onglyza

Type 2 diabetes treatment from AstraZeneca and Bristol-Myers Squibb gets approval in the US

AstraZeneca and Bristol-Myers Squibb (BMS) have received US Food and Drug Administration (FDA) approval for Onglyza (saxagliptin) for the treatment of type 2 diabetes mellitus in adults.

Onglyza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. The once-daily dipeptidyl peptidase-4 (DPP-4) can be used in combination with commonly prescribed oral anti-diabetic medications, such as metformin, sulfonylureas and thiazolidinediones (TZDs), or as a monotherapy to significantly reduce glycosylated haemoglobin levels.

"Type 2 diabetes is a daily challenge for adults patients and physicians. With FDA approval of Onglyza, physicians and adult patients with type 2 diabetes have an important new treatment to help improve glycemic control," said David Brennan, AstraZeneca CEO.

DPP-4 affect the action of incretins; hormones that decrease elevated blood sugar levels by increasing the way the body uses sugar, mainly through increasing insulin production in the pancreas and by reducing the production of glucose in the liver.

The collaboration between AstraZeneca and BMS began in January 2007 with the aim of enabling the two companies to research, develop and commercialise select investigational drugs for type 2 diabetes. 

3rd August 2009

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics